Retraction
Epithelial-Mesenchymal Transition Markers and HER3 Expression Are Predictors of Elisidepsin Treatment Response in Breast and Pancreatic Cancer Cell Lines
Paper Information
Record ID:
52399
Publication Date:
January 08, 2013
Retraction Date:
February 05, 2024
(1.8 year years ago)
Subjects:
Institutions:
Country:
🇪🇸 SpainArticle Type:
Publisher:
PLoS
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1371/journal.pone.0298557Citations (18)
18
Total Citations1
Post-Retraction(5.6%)
16
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
0
Within 30 days
1
Within 1 year
0
After 2+ years
180
Days since retraction (latest)
ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance
Yutao Chen, Anni Lu, Zhangli Hu et al. (5 authors)
Cancer Letters
Open Access
Published: Aug 2024
6 citations
6 citations
180 days after retraction
Retraction: Epithelial-Mesenchymal Transition Markers and HER3 Expression Are Predictors of Elisidepsin Treatment Response in Breast and Pancreatic Cancer Cell Lines
Unknown Authors
PLoS ONE
Open Access
Published: Feb 2024
Same day as retraction
Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model
Tianqi Xu, Alexey Schulga, Е. В. Коновалова et al. (10 authors)
International Journal of Molecular Sciences
Open Access
Published: Feb 2023
6 citations
6 citations
368 days before retraction
Liver Endothelium Microenvironment Promotes HER3-mediated Cell Growth in Pancreatic ductal adenocarcinoma
Wei Zhang, Michelle L. Wright, Moeez Rathore et al. (12 authors)
bioRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: Jun 2022
587 days before retraction
Liver Endothelium Microenvironment Promotes HER3-mediated Cell Growth in Pancreatic Ductal Adenocarcinoma
Moeez Rathore, Wei Zhang, Michelle L. Wright et al. (12 authors)
Journal of Cancer Science and Clinical Therapeutics
Open Access
Published: Jan 2022
5 citations
5 citations
765 days before retraction
Can be marine bioactive peptides (MBAs) lead the future of foodomics for human health?
Abdur Rauf, Anees Ahmed Khalil, Muneeb Khan et al. (10 authors)
Critical Reviews in Food Science and Nutrition
Published: Apr 2021
21 citations
21 citations
1031 days before retraction
Targeting TM4SF5 with anti‑TM4SF5 monoclonal antibody suppresses the growth and motility of human pancreatic cancer cells
Sangkyu Park, Dongbum Kim, Jeong‐A Park et al. (5 authors)
Oncology Letters
Open Access
Published: Nov 2019
6 citations
6 citations
1537 days before retraction
Development of a Novel 3D Tumor-tissue Invasion Model for High-throughput, High-content Phenotypic Drug Screening
Theodore J. Puls, Xiaohong Tan, Mahera Husain et al. (6 authors)
Scientific Reports
Open Access
Published: Aug 2018
68 citations
68 citations
1992 days before retraction
Therapeutic Properties and Biological Benefits of Marine-Derived Anticancer Peptides
Hee Kyoung Kang, Moon‐Chang Choi, Chang‐Seob Seo et al. (4 authors)
International Journal of Molecular Sciences
Open Access
Published: Mar 2018
79 citations
79 citations
2148 days before retraction
3D collagen fibrillar microstructure guides pancreatic cancer cell phenotype and serves as a critical design parameter for phenotypic models of EMT
Theodore J. Puls, Xiaohong Tan, Catherine F. Whittington et al. (4 authors)
PLoS ONE
Open Access
Published: Nov 2017
71 citations
71 citations
2258 days before retraction
Fatty acid synthase affects expression of ErbB receptors in epithelial to mesenchymal transition of breast cancer cells and invasive ductal carcinoma
Tingting Chen, Lan Zhou, Hua Li et al. (8 authors)
Oncology Letters
Open Access
Published: Sep 2017
17 citations
17 citations
2334 days before retraction
Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition
Eva A. Ebbing, Anne Steins, Evelyn Fessler et al. (10 authors)
Gastroenterology
Published: Mar 2017
37 citations
37 citations
2524 days before retraction
Marine Mollusk‐Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance
Maria Letizia Ciavatta, Florence Lefranc, Marianna Carbone et al. (9 authors)
Medicinal Research Reviews
Open Access
Published: Dec 2016
58 citations
58 citations
2616 days before retraction
Phase I, dose-escalating study of elisidepsin (Irvalec®), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors
Sanjay Goel, Santiago Viteri, Teresa Morán et al. (8 authors)
Investigational New Drugs
Published: Dec 2015
9 citations
9 citations
2987 days before retraction
Interplay between YB-1 and IL-6 promotes the metastatic phenotype in breast cancer cells
Bárbara Castellana, Trond Aasen, Gema Moreno‐Bueno et al. (5 authors)
Oncotarget
Open Access
Published: Oct 2015
30 citations
30 citations
3035 days before retraction
Marine Peptides: Bioactivities and Applications
Randy Chi Fai Cheung, Tzi Bun Ng, Jack Ho Wong
Marine Drugs
Open Access
Published: Jun 2015
346 citations
346 citations
3143 days before retraction
Elisidepsin es un compuesto antitumoral de origen marino que causa muerte celular por necrosis relacionada con el contenido lipídico de las líneas celulares tumorales
Susana Esteban Rubio, José Manuel Molina Guijarro
Unknown Journal
Published: Jan 2014
3687 days before retraction
Predictive Factors of Sensitivity to Elisidepsin, a Novel Kahalalide F-Derived Marine Compound
Maria Serova, Armand de Gramont, Ivan Bièche et al. (9 authors)
Marine Drugs
Open Access
Published: Mar 2013
42 citations
42 citations
3974 days before retraction
Quick Stats
Total Citations:
18
Years Since Retraction:
1.8 year
Open Access:
Yes
Last Checked:
Jul 24, 2025